Partner Headlines - BMY

  1. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  2. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  3. Drugmaker AstraZeneca Returns To Growth

    IBD
  4. The Stocks Already in Correction Mode

    FoxBusiness
  5. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  6. Bristol-Myers surprises Street

    IBD
  7. Thursday Morning Earnings Reports

    Benzinga
  8. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  9. Earnings Scheduled For July 24, 2014

    Benzinga
  10. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  11. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  12. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  13. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  14. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  15. Bristol seeks cancer drug nod

    IBD
  16. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  17. Japan approves BMY regimen

    IBD
  18. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  19. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  20. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  21. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  22. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  23. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target ...

    Benzinga
  24. Benzinga's Top Downgrades

    Benzinga
  25. Ex-Dividends For July 1, 2014

    Benzinga
  26. Pfizer and others get EU nods

    IBD
  27. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  28. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  29. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  30. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza ...

    Benzinga
  31. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  32. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  33. BRISTOL-MYERS SQUIBB

    IBD
  34. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab ...

    Benzinga
  35. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  36. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  37. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  38. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  39. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  40. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  41. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  42. Bristol, Merck Q1 sales soft

    IBD
  43. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  44. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, ...

    Benzinga
  45. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  46. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  47. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone ...

    Benzinga
  48. Earnings Scheduled For April 29, 2014

    Benzinga
  49. Stocks To Watch For April 29, 2014

    Benzinga
  50. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  51. Earnings Expectations For The Week Of April 28: Big Oil, Big ...

    Benzinga
  52. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  53. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  54. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  55. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose ...

    Benzinga
  56. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  57. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  58. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  59. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  60. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  61. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  62. Gilead's HCV Challengers Near The Starting Gate

    IBD
  63. Gilead's HCV Challengers Near The Starting Gate

    IBD
  64. Abbott Capturing Incremental Market Share

    GuruFocus
  65. US Stock Futures Jump Ahead Of Economic Data

    Benzinga
  66. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  67. Arrowhead Surges As Analysts Laud Hepatitis B Drug

    IBD
  68. Bristol Moving Ahead With Lung-Cancer Drug Combo

    IBD
  69. Bristol-Myers Squibb's

    IBD
  70. Pfizer Gets Good News For Pneumonia, Bone-Thinner Drugs

    IBD
  71. Market Wrap For February 24: Markets Showing Strength To Start ...

    Benzinga
  72. FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation

    FoxBusiness
  73. Actavis, Forest In $25 Bil Deal

    IBD
  74. Actavis' Buyout Of Forest Creating Spec Pharma Giant

    IBD
  75. Vanguard Health Care Fund's Top Five

    GuruFocus
  76. UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on ...

    Benzinga
  77. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  78. Investors Brace for Bear Market

    FoxBusiness
  79. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  80. #PreMarket Primer: Monday, January 27: Markets Open The Week ...

    Benzinga
  81. Bristol-Myers Int'l Sales Soar

    IBD
  82. Top Earnings-Related Movers for Week of Jan. 20th

    Benzinga
  83. Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

    Benzinga
  84. Bristol Q4 Beats, But Nivolumab Still Worries Market

    IBD
  85. Stocks Open Sharply Lower; Kansas City Southern Collapses

    IBD
  86. Stock Futures Down, Off Lows; Microsoft And Juniper Climb

    IBD
  87. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  88. #PreMarket Primer: Friday, January 24: Growth Fears Drag Down ...

    Benzinga
  89. Earnings Scheduled For January 24, 2014

    Benzinga
  90. Stocks To Watch For January 24, 2014

    Benzinga
  91. Cancer drug result in question

    IBD
  92. Bristol-Myers' New Nivolumab Trial Sparks Worries

    IBD
  93. Growth Fund Of The Year: Stock Picks

    YCharts
  94. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  95. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think ...

    GuruFocus
  96. Ligand Pharmaceuticals Poised For Full-Year Profit

    IBD
  97. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  98. Daclatasvir Marketing Authorization Application for Treatment ...

    Benzinga
  99. The Top Five Drug Launches Of 2013

    IBD
  100. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
Trading Center